Rhubarb single medicine
PreclinicalSmall molecule
Rhubarb single medicine is one of 25 small molecule programs targeting Acute Pancreatitis. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
24
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
26 competitors in Acute Pancreatitis
#DrugCompanyPhaseTrials
1Indocin
CCosette Pharmaceuticals, Inc.
Approved
Merrem
BB. Braun Medical Inc.
Approved
Zocor
OOrganon and Co
Approved
Relistor
SSalix
Approved
Advil
KKenvue Brands
Approved
VIOKACE
DDigestive Care, Inc.
Approved
Symproic
BBioDelivery Sciences International
Phase 3
Indomethacin SR
PPeking Union Medical College Hospital
Phase 3
Bayer Aspirin
BayerPreclinical
Byetta
AstraZenecaPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Rhubarb single medicine. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details